ER-α36, a novel variant of ER-α, mediates estrogen stimulated proliferation of endometrial carcinoma cells via the PKCδ/ERK pathway

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Tong, Jing Shan ^a,b   Zhang, Qing Hua ^b   Wang, Zhen Bo ^b   Li, Sen ^b   Yang, Cai Rong ^b   Fu, Xue Qi ^a   Hou, Yi ^b   Wang, Zhao Yi ^c   Sheng, Jun ^a,d   Sun, Qing Yuan ^b  

^a JILIN UNIVERSITY   (China)

^b INSTITUTE OF ZOOLOGY   (China)

^c CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d YUNNAN AGRICULTURAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; BISINDOLYLMALEIMIDE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA 36; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE C DELTA; ROTTLERIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; BOVINE SERUM ALBUMIN; ISOPROTEIN;

ARTICLE; CARCINOMA CELL; CELL GROWTH; CELL STIMULATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN VARIANT; WESTERN BLOTTING; CELL PROLIFERATION; DRUG EFFECT; ENDOMETRIUM TUMOR; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BOVINAE;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; ENDOMETRIAL NEOPLASMS; ENZYME ACTIVATION; ESTROGEN RECEPTOR ALPHA; ESTROGENS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; PHOSPHORYLATION; PROTEIN ISOFORMS; PROTEIN KINASE C-DELTA; RNA INTERFERENCE; SERUM ALBUMIN, BOVINE; SIGNAL TRANSDUCTION;

EID: 78149476449     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015408     Document Type: Article

References (53)

1. Shang Y (2006) Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Nat Rev Cancer 6: 360-368.
2. Chaudhry P, Asselin E (2009) Resistance to chemotherapy and hormone therapy in endometrial cancer. Endocr Relat Cancer 16: 363-380.
3. Henderson BE, Feigelson HS (2000) Hormonal carcinogenesis. Carcinogenesis 21: 427-433.
4. Muramatsu M, Inoue S (2000) Estrogen receptors: how do they control reproductive and nonreproductive functions? Biochem Biophys Res Commun 270: 1-10.
5. Zhang Y, Wei L, Wang J, Sun T (2003) Role of phosphatase PTEN in the activation of extracellular signal-regulated kinases induced by estradiol in endometrial carcinoma cells. Chin Med J (Engl) 116: 383-387.
6. Rosenfeld MG, Glass CK (2001) Coregulator codes of transcriptional regulation by nuclear receptors. J Biol Chem 276: 36865-36868.
7. Acconcia F, Ascenzi P, Bocedi A, Spisni E, Tomasi V, et al. (2005) Palmitoylation-dependent estrogen receptor alpha membrane localization: regulation by 17beta-estradiol. Mol Biol Cell 16: 231-237.
8. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, et al. (2005) Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochem Biophys Res Commun 336: 1023-1027.
9. Newton AC (1997) Regulation of protein kinase C. Curr Opin Cell Biol 9: 161-167.
10. Nishizuka Y (1986) Studies and perspectives of protein kinase C. Science 233: 305-312.
11. Nishizuka Y (1988) The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 334: 661-665.
12. Nishizuka Y (1995) Protein kinase C and lipid signaling for sustained cellular responses. FASEB J 9: 484-496.
13. Way KJ, Chou E, King GL (2000) Identification of PKC-isoform-specific biological actions using pharmacological approaches. Trends Pharmacol Sci 21: 181-187.
14. Boyan BD, Sylvia VL, Frambach T, Lohmann CH, Dietl J, et al. (2003) Estrogendependent rapid activation of protein kinase C in estrogen receptor-positive MCF-7 breast cancer cells and estrogen receptor-negative HCC38 cells is membranemediated and inhibited by tamoxifen. Endocrinology 144: 1812-1824.
15. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, et al. (2006) A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci U S A 103: 9063-9068.
16. Vivacqua A, Bonofiglio D, Recchia AG, Musti AM, Picard D, et al. (2006) The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol 20: 631-646.
17. Lin SL, Yan LY, Liang XW, Wang ZB, Wang ZY, et al. (2009) A novel variant of ER-alpha, ER-alpha36 mediates testosterone-stimulated ERK and Akt activation in endometrial cancer Hec1A cells. Reprod Biol Endocrinol 7: 102.
18. Ruhul Quddus M, Latkovich P, Castellani WJ, James Sung C, Steinhoff MM, et al. (2002) Expression of cyclin D1 in normal, metaplastic, hyperplastic endometrium and endometrioid carcinoma suggests a role in endometrial carcinogenesis. Arch Pathol Lab Med 126: 459-463.
19. Kashima H, Shiozawa T, Miyamoto T, Suzuki A, Uchikawa J, et al. (2009) Autocrine stimulation of IGF1 in estrogen-induced growth of endometrial carcinoma cells: involvement of the mitogen-activated protein kinase pathway followed by up-regulation of cyclin D1 and cyclin E. Endocr Relat Cancer 16: 113-122.
20. Caldon CE, Sergio CM, Schutte J, Boersma MN, Sutherland RL, et al. (2009) Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc. Mol Cell Biol 29: 4623-4639.
21. Roy PG, Thompson AM (2006) Cyclin D1 and breast cancer. Breast 15: 718-727.
22. Marino M, Galluzzo P, Ascenzi P (2006) Estrogen signaling multiple pathways to impact gene transcription. Curr Genomics 7: 497-508.
23. Ordonez-Moran P, Munoz A (2009) Nuclear receptors: genomic and nongenomic effects converge. Cell Cycle 8: 1675-1680.
24. Zou Y, Ding L, Coleman M, Wang Z (2009) Estrogen receptor-alpha (ER-alpha) suppresses expression of its variant ER-alpha 36. FEBS Lett 583: 1368-1374.
25. Lin SL, Yan LY, Zhang XT, Yuan J, Li M, et al. ER-alpha36, a variant of ERalpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways. PLoS One 5: e9013.
26. Hsieh YC, Yu HP, Frink M, Suzuki T, Choudhry MA, et al. (2007) G proteincoupled receptor 30-dependent protein kinase A pathway is critical in nongenomic effects of estrogen in attenuating liver injury after traumahemorrhage. Am J Pathol 170: 1210-1218.
27. Muchekehu RW, Harvey BJ (2008) 17beta-estradiol rapidly mobilizes intracellular calcium from ryanodine-receptor-gated stores via a PKC-PKAErk- dependent pathway in the human eccrine sweat gland cell line NCL-SG3. Cell Calcium 44: 276-288.
28. Guo RX, Wei LH, Tu Z, Sun PM, Wang JL, et al. (2006) 17 beta-estradiol activates PI3K/Akt signaling pathway by estrogen receptor (ER)-dependent and ER-independent mechanisms in endometrial cancer cells. J Steroid Biochem Mol Biol 99: 9-18.
29. Collins P, Webb C (1999) Estrogen hits the surface. Nat Med 5: 1130-1131.
30. Watson CS, Campbell CH, Gametchu B (1999) Membrane oestrogen receptors on rat pituitary tumour cells: immuno-identification and responses to oestradiol and xenoestrogens. Exp Physiol 84: 1013-1022.
31. Zhang L, Li X, Zhao L, Zhang G, Wang J, et al. (2009) Nongenomic effect of estrogen on the MAPK signaling pathway and calcium influx in endometrial carcinoma cells. J Cell Biochem 106: 553-562.
32. Deucher A, Efimova T, Eckert RL (2002) Calcium-dependent involucrin expression is inversely regulated by protein kinase C (PKC)alpha and PKCdelta. J Biol Chem 277: 17032-17040.
33. Reyland ME (2007) Protein kinase Cdelta and apoptosis. Biochem Soc Trans 35: 1001-1004.
34. Brodie C, Blumberg PM (2003) Regulation of cell apoptosis by protein kinase c delta. Apoptosis 8: 19-27.
35. Liu JF, Crepin M, Liu JM, Barritault D, Ledoux D (2002) FGF-2 and TPA induce matrix metalloproteinase-9 secretion in MCF-7 cells through PKC activation of the Ras/ERK pathway. Biochem Biophys Res Commun 293: 1174-1182.
36. Grossoni VC, Falbo KB, Kazanietz MG, de Kier Joffe ED, Urtreger AJ (2007) Protein kinase C delta enhances proliferation and survival of murine mammary cells. Mol Carcinog 46: 381-390.
37. Li W, Jiang YX, Zhang J, Soon L, Flechner L, et al. (1998) Protein kinase Cdelta is an important signaling molecule in insulin-like growth factor I receptormediated cell transformation. Mol Cell Biol 18: 5888-5898.
38. Sinha R, Kiley SC, Lu JX, Thompson HJ, Moraes R, et al. (1999) Effects of methylselenocysteine on PKC activity, cdk2 phosphorylation and gadd gene expression in synchronized mouse mammary epithelial tumor cells. Cancer Lett 146: 135-145.
39. Koivunen J, Aaltonen V, Peltonen J (2006) Protein kinase C (PKC) family in cancer progression. Cancer Lett 235: 1-10.
40. Koivunen J, Aaltonen V, Koskela S, Lehenkari P, Laato M, et al. (2004) Protein kinase C alpha/beta inhibitor Go6976 promotes formation of cell junctions and inhibits invasion of urinary bladder carcinoma cells. Cancer Res 64: 5693-5701.
41. Nakagawa S, Fujii T, Yokoyama G, Kazanietz MG, Yamana H, et al. (2003) Cell growth inhibition by all-trans retinoic acid in SKBR-3 breast cancer cells: involvement of protein kinase Calpha and extracellular signal-regulated kinase mitogen-activated protein kinase. Mol Carcinog 38: 106-116.
42. Jiang XH, Tu SP, Cui JT, Lin MC, Xia HH, et al. (2004) Antisense targeting protein kinase C alpha and beta1 inhibits gastric carcinogenesis. Cancer Res 64: 5787-5794.
43. Leirdal M, Sioud M (1999) Ribozyme inhibition of the protein kinase C alpha triggers apoptosis in glioma cells. Br J Cancer 80: 1558-1564.
44. Singleton DW, Feng Y, Burd CJ, Khan SA (2003) Nongenomic activity and subsequent c-fos induction by estrogen receptor ligands are not sufficient to promote deoxyribonucleic acid synthesis in human endometrial adenocarcinoma cells. Endocrinology 144: 121-128.
45. Zhang Z, Maier B, Santen RJ, Song RX (2002) Membrane association of estrogen receptor alpha mediates estrogen effect on MAPK activation. Biochem Biophys Res Commun 294: 926-933.
46. Song RX, McPherson RA, Adam L, Bao Y, Shupnik M, et al. (2002) Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol Endocrinol 16: 116-127.
47. Ueda Y, Hirai S, Osada S, Suzuki A, Mizuno K, et al. (1996) Protein kinase C activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf. J Biol Chem 271: 23512-23519.
48. Qiu ZH, Leslie CC (1994) Protein kinase C-dependent and -independent pathways of mitogen-activated protein kinase activation in macrophages by stimuli that activate phospholipase A2. J Biol Chem 269: 19480-19487.
49. Knudsen KE, Arden KC, Cavenee WK (1998) Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. J Biol Chem 273: 20213-20222.
50. Quelle DE, Ashmun RA, Shurtleff SA, Kato JY, Bar-Sagi D, et al. (1993) Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev 7: 1559-1571.
51. Cao QJ, Einstein MH, Anderson PS, Runowicz CD, Balan R, et al. (2002) Expression of COX-2, Ki-67, cyclin D1, and P21 in endometrial endometrioid carcinomas. Int J Gynecol Pathol 21: 147-154.
52. Schmitt JM, Abell E, Wagner A, Davare MA () ERK activation and cell growth require CaM kinases in MCF-7 breast cancer cells. Mol Cell Biochem 335: 155-171.
53. Shiozawa T, Miyamoto T, Kashima H, Nakayama K, Nikaido T, et al. (2004) Estrogen-induced proliferation of normal endometrial glandular cells is initiated by transcriptional activation of cyclin D1 via binding of c-Jun to an AP-1 sequence. Oncogene 23: 8603-8610.